Journal
JOURNAL OF INFECTIOUS DISEASES
Volume 190, Issue 8, Pages 1472-1475Publisher
OXFORD UNIV PRESS INC
DOI: 10.1086/423853
Keywords
-
Categories
Funding
- NIAID NIH HHS [AI35257] Funding Source: Medline
Ask authors/readers for more resources
Background. We measured the effect of low-level fluoroquinolone resistance in Streptococcus pneumoniae on the development of high-level resistance within the context of the mutant selection window. Methods. Rabbits infected with S. pneumoniae were treated with ciprofloxacin or moxifloxacin concentrations that simulated pharmacokinetics in treated humans; bacteria obtained from lungs were examined for fluoroquinolone susceptibility. Results. Ciprofloxacin enriched resistant mutants from a wild-type strain; moxifloxacin did not. However, moxifloxacin enriched resistant mutants from a parC mutant; the drug concentration at the top of the selection window was determined. Conclusions. A parC resistance mutation facilitates the enrichment of high-level resistance, as was predicted by in vitro measurements.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available